Working... Menu
Trial record 91 of 101 for:    Risedronate

Resolution of Effect of Bisphosphonates on Bone in Postmenopausal Osteoporosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01406613
Recruitment Status : Completed
First Posted : August 1, 2011
Last Update Posted : February 15, 2019
University of Sheffield
Information provided by (Responsible Party):
Sheffield Teaching Hospitals NHS Foundation Trust

Brief Summary:

This is a 2year observational study that will recruit patients who have previously completed a randomised, open label, parallel, single centre study (TRIO Study) of three bisphosphonates: alendronate, ibandronate and risedronate. These drugs are the most commonly used group of treatments for postmenopausal osteoporosis in the UK. However, the length of time for which these treatments continue to work after they are stopped has not been fully elucidated. Without this information it is unclear as to how long doctors should treat and whether it would be good practice to give drug 'holidays'.

The investigators plan to compare the effects on bone quantity and quality of stopping these licensed bisphosphonates in patients who have taken the medication for a duration of two years. The investigators aim to recruit up to 100 postmenopausal and up to 100 premenopausal (reference range) subjects. Measurements collected at the final visit of the previous study will be used for 'baseline' values for this study.

The postmenopausal group will have an initial study visit to secure informed consent, and then further study visits at 24, 48, 72 and 96 weeks after stopping medication. Visit procedures will include:

Blood and urine samples for measurements of bone biomarkers Bone Mineral Density of the spine, hip, whole body, forearm Dual-emission X-ray absorptiometry (DXA), and heel dual X-ray and Laser (DXL) Quantitative Ultrasound of Bone (QUS) Vertebral Fracture Assessment (VFA).

The premenopausal group will have one study visit, 96 weeks after completing the previous study. Visit procedures will include:

Blood and urine samples for measurements of bone biomarkers Bone Mineral Density of the spine and hip (DXA)

A subgroup of 50 premenopausal women will also have the following measurements:

Bone Mineral Density of the whole body, forearm (DXA), and heel (DXL) Quantitative Ultrasound of Bone (QUS).

Condition or disease Intervention/treatment
Postmenopausal Osteoporosis Other: Observation

  Show Detailed Description

Layout table for study information
Study Type : Observational
Actual Enrollment : 86 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A 2-year Observational Study of Bone Density and Bone Turnover After Prior Treatment With Alendronate, Ibandronate and Risedronate for Postmenopausal Osteoporosis in Secondary Care
Actual Study Start Date : March 2010
Actual Primary Completion Date : November 2015
Actual Study Completion Date : November 2015

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Particpants of previous TRIO study
All participants to this study are being observed as a follow up to a previous study which involved 4 arms. All participants to this follow up study will be subject to identical study procedures.
Other: Observation
In this study we will examine the changes in bone density by DXA and QUS and bone turnover after stopping Bisphosphonate treatment. As we wish to measure the speed of offset of effects of treatment we have scheduled visits at 24 week intervals in order to fully assess this effect.

Biospecimen Retention:   Samples With DNA

A venous blood sample will be collected from each participant at each visit to analyse biochemical bone markers, and basic biochemistry analysis for eligibility screening.

Two urine samples will be collected from each participant at each study visit, one collected on the morning prior to the study visit and a second sample on the morning of the study visit.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 87 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Participants of previous TRIO study - women who either received treatment with alendronate, ibandronate and risedronate for postmenopausal osteoporosis in secondary care. Control premenopausal women will also be recruited.

Inclusion Criteria:

Inclusion Criteria for postmenopausal women

  • female be at least 7 years postmenopausal but less than 87 years of age
  • be ambulatory
  • be able and willing to participate in the study and provide written informed consent.
  • have taken a bisphosphonate for 2 years as a participant in the TRIO study and be compliant > 80%
  • have a Bone Mineral Density (BMD) T score > -2.5 at the femoral neck

Inclusion Criteria for premenopausal women

  • be able and willing to participate in the study and provide written informed consent
  • have previously taken part as premenopausal controls in the TRIO study
  • be in good general health as determined by past medical and physical history
  • be bisphosphonate naive; premenopausal women.

Exclusion Criteria:

Exclusion Criteria for postmenopausal women:

  • An incident vertebral fracture or more than 5%/year bone loss at the spine or hip during the 2-year TRIO study
  • Evidence of a clinically significant organic disease which could prevent the patient from completing the study, including diabetes
  • Abuse of alcohol or use of illicit drugs or who consumed more than 4 units of any alcoholic beverage one day prior to the visit (i.e. subjects who might be binge drinkers)
  • A history of cancer within the past 5 years excluding skin cancer non melanomas
  • A history of ongoing conditions or diseases known to cause abnormalities of calcium metabolism or skeletal health (secondary osteoporosis)
  • Chronic renal disease (as defined by a creatinine clearance of ≤ 30ml/min)
  • Acute or chronic hepatic disease
  • Malabsorption syndromes
  • Hyperthyroidism as manifested by Thyrotrophin-stimulating hormone (TSH) outside the lower limit of the normal range
  • Hyperparathyroidism
  • Hypocalcemia or hypercalcemia
  • Osteomalacia
  • Cushing's syndrome
  • Current use of glucocorticoid therapy
  • A serum calcium less than 2.2 mmol/l and a Parathyroid hormone (PTH) above 75ng/l
  • A history of any known condition that would interfere with the assessment of Dual-emission X-ray absorptiometry (DXA) at either lumbar spine or femoral neck
  • Markedly abnormal clinical laboratory parameters that are assessed as clinically significant by the principal investigator
  • Require, in the opinion of the consulting physician, continuation of bisphosphonate therapy.

Exclusion Criteria for premenopausal women:

  • Are pregnant or nursing (lactating)
  • Use of any hormonal forms of contraception/ therapy within the past 2 years that would, in the opinion of the consulting physician, affect bone metabolism.
  • Use of anabolic agents such as steroids or PTH, or any bisphosphonate within the past 2 years.
  • Have any history of cancer within the past 5 years. Relatively benign skin malignancies, such as basal cell carcinoma or squamous cell carcinoma, are not an exclusion if the patient has been in remission for at least 6 months prior to enrolment.
  • Have any chronic disease (HIV or AIDs, clinically significant renal or cardiovascular disease, hyperthyroidism, diabetes, hyperlipidemia) or menstrual cycle irregularity (by history)).
  • Have any metabolic bone disease, such as osteoporosis, Paget 's disease, osteogenesis imperfecta, or serious illness affecting normal bone homeostasis (by history and physical exam if required)
  • Significant use of any medications known to affect bone metabolism (such as Phenytoin or other anticonvulsants, Selective Estrogen Receptor Modulators (SERMs), heparin or systemic glucocorticosteroids) within the past 2 years.
  • Have suffered a fracture within the last 12 months
  • Have anorexia nervosa, suspected bulimia (by history or physical) or obvious malnutrition
  • Have a history of alcoholism, or who have consumed more than 4 units of any alcoholic beverage one day prior to the visit (i.e., subjects who might be binge drinkers)
  • Have previously participated in active therapy clinical trials within the last 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01406613

Layout table for location information
United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, South Yorks, United Kingdom, S5 7AU
Sponsors and Collaborators
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield
Layout table for investigator information
Principal Investigator: Richard Eastell, Professor University of Sheffield

Layout table for additonal information
Responsible Party: Sheffield Teaching Hospitals NHS Foundation Trust Identifier: NCT01406613     History of Changes
Other Study ID Numbers: STH15387
First Posted: August 1, 2011    Key Record Dates
Last Update Posted: February 15, 2019
Last Verified: February 2019

Keywords provided by Sheffield Teaching Hospitals NHS Foundation Trust:
Bone Density

Additional relevant MeSH terms:
Layout table for MeSH terms
Risedronic Acid
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Ibandronic Acid
Bone Density Conservation Agents
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents